Shaojiong Zhou, Jiahua Xu, Xiaoduo Liu, Aonan Li, Bo Zhao, Chaofan Geng, Tao Wei, Yunzhe Liu, Zhibin Wang, Yi Tang
{"title":"中国COVID-19康复患者的脑雾评估:一项开发和验证研究。","authors":"Shaojiong Zhou, Jiahua Xu, Xiaoduo Liu, Aonan Li, Bo Zhao, Chaofan Geng, Tao Wei, Yunzhe Liu, Zhibin Wang, Yi Tang","doi":"10.1080/00207454.2024.2398616","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Post coronavirus disease 2019 (COVID-19) pandemic, the widespread emergence and persistence of brain fog has led to a decline in people's productivity and quality of life. However, the clinical characteristics of COVID-19-associated brain fog are unclear, and standardized assessments are lacking. This study aims to develop a scale for brain fog assessment and support clinical practice and research.</p><p><strong>Methods: </strong>The 17-item Brain Fog Assessment (BFA) scale was developed using a standardized methodology, including literature review, focus group discussions (FGDs), expert evaluation, and psychometric validation. Eighteen potential items were generated following the literature review. These items were subsequently refined during FGDs, which included input from patients, caregivers, and multidisciplinary experts in neurology, cognitive neuroscience, and psychology. After thorough deliberation and expert evaluation, the item pool was finalized into a 17-item scale. We recruited 1,325 patients recovered from COVID-19 from Chinese communities. Psychometric properties were assessed by reliability and validity analysis.</p><p><strong>Results: </strong>Exploratory factor analysis of the BFA scale revealed a three-factor mode comprising 'cognitive decline' (nine items), 'confusion - disorientation' (five items), and 'fatigue' (three items). The internal consistency of each factor was strong (Cronbach's α: 0.82-0.92). Confirmatory factor analysis showed that the model fit, convergent validity, and discriminant validity of the scale were satisfactory. The test-retest reliability was strong (intraclass correlation coefficient = 0.84). Criterion-related validity analysis showed a strong correlation to the Wood Mental Fatigue Inventory (<i>r</i> = 0.70, <i>p</i> < 0.001). Individuals with a higher BFA score tended to score lower on the Montreal Cognitive Assessment (<i>r</i> = -0.23, <i>p</i> = 0.015).</p><p><strong>Conclusions: </strong>We established a novel BFA scale to quantify multiple clinical aspects of COVID-19-associated brain fog. Using the BFA scale, fatigue and declining performance in memory, attention, and thought were identified as the main symptoms of COVID-19-associated brain fog. This scale has potential implications for disease monitoring and therapy development for individuals with COVID-19-associated brain fog.</p>","PeriodicalId":14161,"journal":{"name":"International Journal of Neuroscience","volume":" ","pages":"1-11"},"PeriodicalIF":1.7000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Brain fog assessment in patients recovered from COVID-19 in China: a development and validation study.\",\"authors\":\"Shaojiong Zhou, Jiahua Xu, Xiaoduo Liu, Aonan Li, Bo Zhao, Chaofan Geng, Tao Wei, Yunzhe Liu, Zhibin Wang, Yi Tang\",\"doi\":\"10.1080/00207454.2024.2398616\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Post coronavirus disease 2019 (COVID-19) pandemic, the widespread emergence and persistence of brain fog has led to a decline in people's productivity and quality of life. However, the clinical characteristics of COVID-19-associated brain fog are unclear, and standardized assessments are lacking. This study aims to develop a scale for brain fog assessment and support clinical practice and research.</p><p><strong>Methods: </strong>The 17-item Brain Fog Assessment (BFA) scale was developed using a standardized methodology, including literature review, focus group discussions (FGDs), expert evaluation, and psychometric validation. Eighteen potential items were generated following the literature review. These items were subsequently refined during FGDs, which included input from patients, caregivers, and multidisciplinary experts in neurology, cognitive neuroscience, and psychology. After thorough deliberation and expert evaluation, the item pool was finalized into a 17-item scale. We recruited 1,325 patients recovered from COVID-19 from Chinese communities. Psychometric properties were assessed by reliability and validity analysis.</p><p><strong>Results: </strong>Exploratory factor analysis of the BFA scale revealed a three-factor mode comprising 'cognitive decline' (nine items), 'confusion - disorientation' (five items), and 'fatigue' (three items). The internal consistency of each factor was strong (Cronbach's α: 0.82-0.92). Confirmatory factor analysis showed that the model fit, convergent validity, and discriminant validity of the scale were satisfactory. The test-retest reliability was strong (intraclass correlation coefficient = 0.84). Criterion-related validity analysis showed a strong correlation to the Wood Mental Fatigue Inventory (<i>r</i> = 0.70, <i>p</i> < 0.001). Individuals with a higher BFA score tended to score lower on the Montreal Cognitive Assessment (<i>r</i> = -0.23, <i>p</i> = 0.015).</p><p><strong>Conclusions: </strong>We established a novel BFA scale to quantify multiple clinical aspects of COVID-19-associated brain fog. Using the BFA scale, fatigue and declining performance in memory, attention, and thought were identified as the main symptoms of COVID-19-associated brain fog. This scale has potential implications for disease monitoring and therapy development for individuals with COVID-19-associated brain fog.</p>\",\"PeriodicalId\":14161,\"journal\":{\"name\":\"International Journal of Neuroscience\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/00207454.2024.2398616\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00207454.2024.2398616","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景:冠状病毒病 2019(COVID-19)大流行后,脑雾的广泛出现和持续存在导致人们的工作效率和生活质量下降。然而,COVID-19相关脑雾的临床特征尚不明确,也缺乏标准化的评估。本研究旨在开发脑雾评估量表,为临床实践和研究提供支持:方法:采用标准化方法,包括文献综述、焦点小组讨论 (FGD)、专家评估和心理测量验证,开发了 17 个项目的脑雾评估量表 (BFA)。在文献综述后产生了 18 个潜在项目。随后,患者、护理人员以及神经病学、认知神经科学和心理学等多学科专家参与的焦点小组讨论对这些项目进行了改进。经过充分讨论和专家评估,项目库最终确定了 17 个项目的量表。我们从中国社区招募了 1,325 名 COVID-19 康复患者。通过信度和效度分析评估了心理测量特性:BFA量表的探索性因子分析显示了由 "认知能力下降"(9个条目)、"困惑-迷失方向"(5个条目)和 "疲劳"(3个条目)组成的三因子模式。每个因子的内部一致性都很好(Cronbach's α:0.82-0.92)。确认性因素分析表明,量表的模型拟合度、收敛效度和区分效度均令人满意。测试-再测信度较高(类内相关系数=0.84)。标准相关效度分析表明,该量表与伍德精神疲劳量表有很强的相关性(r = 0.70, p r = -0.23, p = 0.015):我们建立了一个新的BFA量表,用于量化COVID-19相关脑雾的多个临床方面。使用 BFA 量表,疲劳和记忆力、注意力和思维能力下降被确定为 COVID-19 相关脑雾的主要症状。该量表对COVID-19相关脑雾患者的疾病监测和治疗开发具有潜在意义。
Brain fog assessment in patients recovered from COVID-19 in China: a development and validation study.
Background: Post coronavirus disease 2019 (COVID-19) pandemic, the widespread emergence and persistence of brain fog has led to a decline in people's productivity and quality of life. However, the clinical characteristics of COVID-19-associated brain fog are unclear, and standardized assessments are lacking. This study aims to develop a scale for brain fog assessment and support clinical practice and research.
Methods: The 17-item Brain Fog Assessment (BFA) scale was developed using a standardized methodology, including literature review, focus group discussions (FGDs), expert evaluation, and psychometric validation. Eighteen potential items were generated following the literature review. These items were subsequently refined during FGDs, which included input from patients, caregivers, and multidisciplinary experts in neurology, cognitive neuroscience, and psychology. After thorough deliberation and expert evaluation, the item pool was finalized into a 17-item scale. We recruited 1,325 patients recovered from COVID-19 from Chinese communities. Psychometric properties were assessed by reliability and validity analysis.
Results: Exploratory factor analysis of the BFA scale revealed a three-factor mode comprising 'cognitive decline' (nine items), 'confusion - disorientation' (five items), and 'fatigue' (three items). The internal consistency of each factor was strong (Cronbach's α: 0.82-0.92). Confirmatory factor analysis showed that the model fit, convergent validity, and discriminant validity of the scale were satisfactory. The test-retest reliability was strong (intraclass correlation coefficient = 0.84). Criterion-related validity analysis showed a strong correlation to the Wood Mental Fatigue Inventory (r = 0.70, p < 0.001). Individuals with a higher BFA score tended to score lower on the Montreal Cognitive Assessment (r = -0.23, p = 0.015).
Conclusions: We established a novel BFA scale to quantify multiple clinical aspects of COVID-19-associated brain fog. Using the BFA scale, fatigue and declining performance in memory, attention, and thought were identified as the main symptoms of COVID-19-associated brain fog. This scale has potential implications for disease monitoring and therapy development for individuals with COVID-19-associated brain fog.
期刊介绍:
The International Journal of Neuroscience publishes original research articles, reviews, brief scientific reports, case studies, letters to the editor and book reviews concerned with problems of the nervous system and related clinical studies, epidemiology, neuropathology, medical and surgical treatment options and outcomes, neuropsychology and other topics related to the research and care of persons with neurologic disorders. The focus of the journal is clinical and transitional research. Topics covered include but are not limited to: ALS, ataxia, autism, brain tumors, child neurology, demyelinating diseases, epilepsy, genetics, headache, lysosomal storage disease, mitochondrial dysfunction, movement disorders, multiple sclerosis, myopathy, neurodegenerative diseases, neuromuscular disorders, neuropharmacology, neuropsychiatry, neuropsychology, pain, sleep disorders, stroke, and other areas related to the neurosciences.